EAT is up +49.38%% since April’24 pick View All Top Buy Picks

Zymeworks Inc Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 86.52. In total, the insiders bought 15 091 482 and sold 134 010 ZYME shares in the last 100 trades.

Insider Power

(Last 100 transactions)
86.52
Buy 15 091 482 Shares
Sell 134 010 Shares

Historical Insider Trades

Date Type Action Person Amount
Apr 02, 2024 Stock Option (Right to Buy) Buy Gallagher Neil 74 000
Apr 02, 2024 No securities are beneficially owned Buy Gallagher Neil 0
Feb 22, 2024 Buy Platshon Scott 0
Feb 08, 2024 Stock Option (Right to Buy) Buy Cesano Alessandra 74 000
Feb 08, 2024 No securities are beneficially owned Buy Cesano Alessandra 0
Jan 08, 2024 Common Stock Sell Galbraith Kenneth 5 706
Jan 08, 2024 Common Stock Sell Astle Christopher 1 431
Jan 08, 2024 Common Stock Sell Moore Paul Andrew 2 339
Jan 05, 2024 Stock Option (Right to Buy) Buy Galbraith Kenneth 300 000
Jan 05, 2024 Restricted Stock Unit Buy Galbraith Kenneth 200 000
Jan 05, 2024 Restricted Stock Unit Sell Galbraith Kenneth 47 666
Jan 05, 2024 Common Stock Buy Galbraith Kenneth 47 666
Jan 05, 2024 Common Stock Sell Galbraith Kenneth 18 198
Jan 05, 2024 Stock Option (Right to Buy) Buy Astle Christopher 50 000
Jan 05, 2024 Restricted Stock Unit Buy Astle Christopher 30 000
Jan 05, 2024 Restricted Stock Unit Sell Astle Christopher 10 500
Jan 05, 2024 Common Stock Buy Astle Christopher 10 500
Jan 05, 2024 Common Stock Sell Astle Christopher 4 563
Jan 05, 2024 Stock Option (Right to Buy) Buy Moore Paul Andrew 90 000
Jan 05, 2024 Restricted Stock Unit Buy Moore Paul Andrew 60 000
Jan 05, 2024 Restricted Stock Unit Sell Moore Paul Andrew 17 166
Jan 05, 2024 Common Stock Buy Moore Paul Andrew 17 166
Jan 05, 2024 Common Stock Sell Moore Paul Andrew 7 460
Jan 05, 2024 Stock Option (Right to Buy) Buy Smith Jeffrey T L 90 000
Jan 05, 2024 Restricted Stock Unit Buy Smith Jeffrey T L 60 000
Click to get the best stock tips daily for free!

About Zymeworks Inc

Zymeworks Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 ... ZYME Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT